PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences.
ZimVie will be presenting at the upcoming Stifel 2024 Jaws & Paws Conference. ZimVie’s management is scheduled to present on Thursday, May 30, 2024, at 11:30 a.m. Eastern Time.
ZimVie’s management will also be presenting at the 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024, at 3:20 p.m. Eastern Time.
Interested parties may access a live audio webcast of the presentations by visiting the “Investors” section of the company’s website at investor.zimvie.com.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Media Contact Information:
ZimVie
Allison Johnson • This email address is being protected from spambots. You need JavaScript enabled to view it.
(774) 266-8046
ZimVie
Grace Flowers • This email address is being protected from spambots. You need JavaScript enabled to view it.
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Marissa Bych • This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$18.97 |
Daily Volume: | 60,650 |
Market Cap: | US$535.140M |
October 10, 2025 July 30, 2025 July 23, 2025 July 21, 2025 June 05, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load